ris: A review of IL-31RA blockade and other potential treatments.Dermatol Ther (Heidelb).2022;12(9):2039–2048. doi: 10.1007/s13555- 022-00782-2

Kwatra SG, Misery L, Clibborn C, Steinhoff M. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics.Clin Transl Immunology. 2022;11(5):e1390. doi: 10.1002/cti2.1390








Contacts


Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessi
=*=*=*=*=*=
当前为第9/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页